Drug Type Monoclonal antibody |
Synonyms Recombinant anti-VEGFR2 chimeric monoclonaly antibody (Changchun Genescience), GenSci-043, GenSci043 + [1] |
Target |
Action antagonists |
Mechanism VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
stomach adenocarcinoma | Phase 3 | China | 30 May 2022 | |
Advanced Gastroesophageal Junction Adenocarcinoma | Phase 3 | China | 20 May 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | China | 11 Nov 2019 | |
Gastrooesophageal junction cancer | Phase 2 | China | 01 Aug 2019 | |
Liver metastases | Phase 2 | China | 01 Aug 2019 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 1 | China | 02 Apr 2021 | |
metastatic non-small cell lung cancer | Phase 1 | China | 02 Apr 2021 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | China | 25 Mar 2021 | |
Malignant Solid Neoplasm | Phase 1 | China | 12 Oct 2017 | |
Metastatic Solid Tumor | Phase 1 | China | 11 Oct 2017 |